BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myelogenous leukemia (CML), XN has also been shown to degrade the BCR-ABL fusion oncoprotein through caspase-mediated apoptosis [15], as well as via MAPK-related signaling pathways, including ERK and JNK [16,99].